← Leaderboards
Lihua Elizabeth Budde
Beckman Research Institute/City Of Hope
$959,566
Attributed
$2,401,768
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $489.2K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,401,768 · 1
By mechanism
R01$2,401,768 · 1
Top collaborators
- Michael A Caligiuri5 shared
- Jianhua Yu3 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Guido Marcucci$19,718,636
- Wenyong Chen$3,166,948
- Bin Zhang$2,891,856
- Jianhua Yu$11,234,533
- Xiuli Wang$2,702,470
Others in their field
Other Emerging Leaders on “Acute Lymphocytic Leukemia”
- Crystal Mackall · Children'S Hosp Of Philadelphia$12,361,966
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$8,557,384
- Adam De Smith · University Of Southern California$5,277,579
- Karen R Rabin · Baylor College Of Medicine$4,946,686
- Ernesto Guccione · Icahn School Of Medicine At Mount Sinai$4,876,508
Research focus
Acute Lymphocytic LeukemiaAcute Myeloid Leukemia CellAffectAcute Myelocytic LeukemiaAntigensAntigen TargetingAntileukemic ActivityBackB-Cell LymphomasAllogenicBloodB Lymphoid MalignancyBone MarrowCaringCar T Cell TherapyCd19 GeneCell LineCell SurfaceCell TherapyChimeric Antigen ReceptorBiologicalChimeric Antigen Receptor T CellsClinically RelevantClinical Research
Grant awards (5)
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$489,159
R01 · FY2025 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$464,700
R01 · FY2024 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2023 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2022 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$489,159
R01 · FY2021 · CA